Merck net sales down by 4% in Q3 2012
The firm’s GAAP net income for the third quarter declined to $1.79bn, down from $2.02bn for the same quarter in 2011. Merck’s pharmaceutical sales in the third quarter
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
Under the collaboration, Lonza will develop and manufacture demcizumab, anti-Notch 2/3 projects, anti-Fzd7, anti-Notch, anti-DLL4/VEGF Bi-Specific, including many other monoclonal antibodies at its mammalian manufacturing facility in Slough,